Clinical Approach to Rash
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of rash
Rash is one of the most common presenting complaints in clinical practice, accounting for approximately 7% of all outpatient visits in the United States. Dermatological conditions represent the fourth most common reason for primary care consultations, with an estimated 85 million visits annually. The skin, as the body’s largest organ, serves as a window to both localized cutaneous disease and systemic illness. Approximately 15-20% of skin eruptions are manifestations of underlying systemic conditions, making accurate diagnosis crucial for patient management.
Definition
A rash (exanthem) is any change in the skin’s appearance, including alterations in color, texture, or elevation. It represents the cutaneous manifestation of various pathological processes including inflammation, infection, immune dysregulation, vascular abnormalities, or neoplastic proliferation. Rashes may be localized or generalized, symptomatic or asymptomatic, and may indicate primary skin disease or systemic illness.
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute | Less than 2 weeks | Viral exanthems, drug eruptions, acute urticaria, contact dermatitis, cellulitis | Often self-limiting; requires exclusion of serious causes such as drug hypersensitivity syndrome or sepsis |
| Subacute | 2 to 6 weeks | Pityriasis rosea, secondary syphilis, persistent drug reactions, evolving autoimmune conditions | May represent resolving acute process or early chronic condition; warrants investigation if not improving |
| Chronic | Greater than 6 weeks | Psoriasis, eczema, chronic urticaria, lichen planus, cutaneous lupus, dermatomyositis | Often indicates underlying inflammatory, autoimmune, or neoplastic process; requires systematic evaluation |
Classification by Primary Lesion Morphology
Key Concept: Accurate description of the primary lesion is the foundation of dermatological diagnosis. The morphology provides the most important clue to etiology.
| Lesion Type | Definition | Clinical Examples |
|---|---|---|
| Macule | Flat, non-palpable lesion less than 1 cm; change in color only | Freckles, petechiae, vitiligo, measles early stage |
| Patch | Flat, non-palpable lesion greater than 1 cm | Vitiligo, café-au-lait spots, tinea versicolor |
| Papule | Elevated, palpable lesion less than 1 cm | Warts, molluscum contagiosum, lichen planus, insect bites |
| Plaque | Elevated, palpable lesion greater than 1 cm; often formed by coalescence of papules | Psoriasis, eczema, mycosis fungoides |
| Vesicle | Fluid-filled lesion less than 1 cm | Herpes simplex, varicella, dyshidrotic eczema |
| Bulla | Fluid-filled lesion greater than 1 cm | Bullous pemphigoid, pemphigus vulgaris, burns |
| Pustule | Pus-filled lesion of any size | Acne, folliculitis, pustular psoriasis |
| Wheal (Hive) | Transient, edematous, pink papule or plaque | Urticaria, angioedema |
| Nodule | Palpable, solid lesion greater than 1 cm extending into dermis or subcutis | Erythema nodosum, lipoma, cyst |
| Purpura | Non-blanching red-purple discoloration due to extravasated blood | Vasculitis, thrombocytopenia, senile purpura |
Classification by Distribution Pattern
Localized Patterns
Dermatomal: Follows nerve distribution (herpes zoster)
Photo-distributed: Sun-exposed areas (drug photosensitivity, lupus)
Acral: Hands and feet (hand-foot-mouth disease, Rocky Mountain spotted fever)
Flexural: Body folds (atopic dermatitis, inverse psoriasis)
Extensor: Elbows and knees (psoriasis, dermatitis herpetiformis)
Generalized Patterns
Diffuse/Universal: Entire body surface (erythroderma, drug reactions)
Central: Trunk predominant (pityriasis rosea, viral exanthems)
Peripheral: Extremity predominant (erythema multiforme)
Symmetrical: Bilateral mirror distribution (systemic causes)
Asymmetrical: Unilateral or irregular (contact, infection)
Secondary Lesion Changes
| Change | Description | Clinical Significance |
|---|---|---|
| Scale | Accumulation of stratum corneum | Suggests epidermal involvement (psoriasis, eczema, tinea) |
| Crust | Dried serum, blood, or pus on surface | Indicates prior vesicle, erosion, or infection (impetigo) |
| Erosion | Superficial loss of epidermis; heals without scarring | Secondary to vesicle rupture or superficial trauma |
| Ulcer | Loss of epidermis and dermis; heals with scarring | Vascular insufficiency, infection, malignancy, vasculitis |
| Lichenification | Thickening with accentuated skin markings | Chronic rubbing or scratching (chronic eczema) |
| Excoriation | Linear erosion from scratching | Indicates pruritus; look for primary lesions |
The “Big Five” Approach: When evaluating any rash, systematically assess five key features:
- Morphology: What is the primary lesion type?
- Distribution: Where is it located and what pattern does it follow?
- Arrangement: How are lesions grouped (clustered, linear, annular)?
- Color: What color changes are present (erythema, hyperpigmentation, purpura)?
- Associated symptoms: Is there pruritus, pain, or systemic symptoms?
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of cutaneous eruptions
Understanding the pathophysiology of rash requires knowledge of skin anatomy and the various mechanisms by which cutaneous inflammation and injury occur. The skin consists of three main layers: the epidermis (stratified squamous epithelium providing barrier function), the dermis (connective tissue containing blood vessels, nerves, and appendages), and the subcutis (adipose tissue). Rashes develop through disturbances in any of these layers via inflammatory, infectious, vascular, or neoplastic processes.
Relevant Skin Anatomy
| Layer | Key Components | Role in Rash Formation |
|---|---|---|
| Epidermis | Keratinocytes, melanocytes, Langerhans cells, Merkel cells | Barrier disruption causes scaling and erosions; immune activation triggers inflammation; melanocyte dysfunction causes pigmentary changes |
| Dermoepidermal Junction | Basement membrane zone with hemidesmosomes and anchoring fibrils | Autoantibody targeting causes blistering diseases (bullous pemphigoid, epidermolysis bullosa acquisita) |
| Dermis | Collagen, elastin, blood vessels, lymphatics, mast cells, fibroblasts | Vascular dilation causes erythema; vessel damage causes purpura; edema causes wheals; inflammation causes papules and plaques |
| Subcutis | Adipose tissue, larger vessels, nerves | Panniculitis causes tender nodules (erythema nodosum); deep infections cause cellulitis |
Immunological Mechanisms of Rash
Key Concept: Many rashes result from immune-mediated mechanisms. Understanding the Gell and Coombs classification of hypersensitivity reactions helps predict clinical features and guide management.
Type I: Immediate Hypersensitivity
Mechanism: IgE-mediated mast cell degranulation
Timing: Minutes to hours
Mediators: Histamine, leukotrienes, prostaglandins
Clinical examples: Urticaria, angioedema, anaphylaxis
Rash features: Wheals, erythema, pruritus; transient and migratory
Type II: Cytotoxic Hypersensitivity
Mechanism: IgG/IgM antibodies against cell surface antigens
Timing: Hours to days
Mediators: Complement activation, antibody-dependent cellular cytotoxicity
Clinical examples: Pemphigus vulgaris, bullous pemphigoid
Rash features: Blisters and erosions at sites of autoantibody binding
Type III: Immune Complex
Mechanism: Antigen-antibody complex deposition in vessel walls
Timing: Days to weeks
Mediators: Complement, neutrophil infiltration
Clinical examples: Leukocytoclastic vasculitis, serum sickness, lupus
Rash features: Palpable purpura, urticarial vasculitis, livedo
Type IV: Delayed Hypersensitivity
Mechanism: T-cell mediated inflammation
Timing: 24-72 hours to weeks
Mediators: Cytokines (interferon-gamma, tumor necrosis factor), cytotoxic T cells
Clinical examples: Contact dermatitis, drug eruptions, Stevens-Johnson syndrome
Rash features: Eczematous changes, morbilliform eruptions, bullae with necrosis in severe cases
How Common Conditions Cause Rash
| Condition | Pathophysiological Mechanism | Clinical Correlation |
|---|---|---|
| Viral exanthem | Direct viral cytopathic effect on keratinocytes; immune complex deposition; T-cell response to viral antigens in skin | Morbilliform or maculopapular rash; often starts centrally and spreads peripherally; associated with prodromal symptoms |
| Drug eruption (morbilliform) | Type IVb hypersensitivity with CD4+ T-cell activation and cytokine release; typically 7-14 days after drug initiation | Symmetrical, erythematous macules and papules; may have mild pruritus; usually starts on trunk |
| Contact dermatitis | Type IVa hypersensitivity with Langerhans cell presentation of hapten to T cells; subsequent inflammatory cascade | Well-demarcated eczematous plaques conforming to area of contact; vesicles in acute phase; lichenification if chronic |
| Psoriasis | T-helper 17 cell-mediated inflammation with interleukin-17 and interleukin-23 axis activation; keratinocyte hyperproliferation (7-fold increase in turnover) | Well-demarcated erythematous plaques with silvery scale; Koebner phenomenon; nail changes; extensor distribution |
| Urticaria | Mast cell degranulation (IgE-mediated or direct); release of histamine causing vasodilation and increased vascular permeability | Transient wheals lasting less than 24 hours; intense pruritus; dermographism; individual lesion resolves completely |
| Cellulitis | Bacterial invasion (Streptococcus, Staphylococcus) of dermis and subcutis; inflammatory response with neutrophil infiltration; cytokine-mediated systemic response | Expanding area of erythema, warmth, tenderness; poorly defined borders; may have fever and leukocytosis |
| Vasculitis (small vessel) | Immune complex deposition or direct antibody attack on vessel walls; complement activation; neutrophilic infiltration with fibrinoid necrosis | Palpable purpura (non-blanching); lower extremity predominance; may have systemic involvement (kidneys, joints) |
| Stevens-Johnson syndrome/Toxic epidermal necrolysis | Type IVc hypersensitivity with CD8+ cytotoxic T cells and natural killer cells; massive keratinocyte apoptosis via Fas-Fas ligand and granulysin pathways | Mucosal erosions; targetoid lesions progressing to widespread epidermal detachment; positive Nikolsky sign; systemic toxicity |
Non-Immunological Mechanisms
Vascular Mechanisms
Vasodilation: Erythema and blanching
Extravasation: Purpura and petechiae
Thrombosis: Livedo reticularis, necrosis
Clinical relevance: Distinguish blanching (vascular dilation) from non-blanching (hemorrhage) lesions with diascopy
Infectious Mechanisms
Direct invasion: Bacterial, fungal, viral cytopathic effects
Toxin-mediated: Staphylococcal scalded skin syndrome, scarlet fever
Embolic phenomena: Janeway lesions, Osler nodes
Clinical relevance: Pattern and morphology help identify organism and guide empiric therapy
Physical and Environmental
Mechanical: Friction, pressure (calluses, corns)
Thermal: Burns, frostbite
Radiation: Sunburn, radiation dermatitis
Clinical relevance: History of exposure is diagnostic; remove offending agent
Often Overlooked Mechanism: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
This severe drug reaction involves viral reactivation (particularly human herpesvirus 6) alongside drug hypersensitivity. The mechanism involves sequential drug-induced immunosuppression followed by viral reactivation, creating a “two-hit” model. This explains the characteristic delayed onset (2-8 weeks after drug exposure) and the prolonged, relapsing course even after drug discontinuation. Always check for hepatic, renal, and hematologic involvement in any patient with extensive drug eruption and eosinophilia.
Understanding Pruritus in Rash
| Pruritus Pattern | Mechanism | Associated Conditions |
|---|---|---|
| Histamine-mediated | Mast cell degranulation activating H1 receptors on sensory nerves | Urticaria, insect bites; responds well to antihistamines |
| Non-histaminergic | Cytokines (interleukin-31), proteases, neuropeptides (substance P) activating C-fibers | Atopic dermatitis, psoriasis; poor antihistamine response |
| Neuropathic | Damage or dysfunction of peripheral or central sensory neurons | Postherpetic neuralgia, brachioradial pruritus, notalgia paresthetica |
| Psychogenic | Central nervous system processing abnormalities; often associated with anxiety or depression | Neurotic excoriations, delusions of parasitosis |
Clinical Implication of Pathophysiology
Understanding the mechanism guides treatment selection. Histamine-driven urticaria responds to antihistamines, while interleukin-mediated inflammation in psoriasis requires immunomodulatory therapy. Type I reactions warrant epinephrine readiness, while type IV reactions benefit from corticosteroids. Identifying the mechanism early prevents ineffective therapy and guides appropriate intervention.
3. History Taking
A comprehensive approach to eliciting the rash history
Red Flags — Require Urgent Evaluation
- Mucosal involvement — Stevens-Johnson syndrome, toxic epidermal necrolysis, pemphigus vulgaris
- Skin pain out of proportion to appearance — Necrotizing fasciitis, early toxic epidermal necrolysis
- Rapidly spreading erythema with systemic toxicity — Cellulitis, necrotizing soft tissue infection, sepsis
- Petechiae or purpura with fever — Meningococcemia, Rocky Mountain spotted fever, disseminated intravascular coagulation
- Blistering with positive Nikolsky sign — Toxic epidermal necrolysis, staphylococcal scalded skin syndrome, pemphigus
- Facial swelling or tongue involvement — Angioedema, anaphylaxis (airway emergency)
- Fever with diffuse erythema and hypotension — Toxic shock syndrome
- New rash with eosinophilia and organ dysfunction — Drug reaction with eosinophilia and systemic symptoms (DRESS)
Systematic History: The “RASHES” Approach
Use the mnemonic “RASHES” to ensure comprehensive history taking:
- R — Recent exposures and triggers: New medications (within 2-8 weeks), foods, contacts, travel, sick contacts, environmental exposures
- A — Appearance and evolution: What did it look like initially? How has it changed? Spreading pattern? Color changes over time?
- S — Symptoms associated: Pruritus, pain, burning? Fever, malaise, arthralgia, sore throat? Mucosal symptoms (mouth sores, eye irritation, genital lesions)?
- H — History (personal and family): Previous similar episodes? Atopy (eczema, asthma, allergic rhinitis)? Autoimmune diseases? Family history of skin conditions?
- E — Exact location and spread: Where did it start? Where has it spread? Distribution pattern? Symmetric or asymmetric?
- S — Systemic review: Weight loss, night sweats, joint pain, photosensitivity, Raynaud phenomenon, dry eyes/mouth, dysphagia, muscle weakness?
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Drug eruption | Symmetric, starts on trunk, 7-14 days after new medication | “Have you started any new medications in the past 2 months, including over-the-counter drugs, supplements, or herbal remedies?” |
| Viral exanthem | Prodrome of fever, malaise; often in outbreak settings | “Did you have any flu-like symptoms, sore throat, or fever before the rash appeared? Has anyone around you been sick?” |
| Contact dermatitis | Well-demarcated, geometric shapes, exposed areas | “Have you been exposed to any new soaps, detergents, cosmetics, jewelry, plants, or occupational chemicals?” |
| Urticaria | Transient wheals, individual lesions last less than 24 hours | “Do individual spots come and go, or do they stay in the same place? How long does each spot last before fading?” |
| Psoriasis | Well-demarcated plaques with silvery scale, nail changes | “Have you noticed thick, scaly patches on your elbows, knees, or scalp? Any changes in your fingernails or toenails?” |
| Scabies | Intense nocturnal pruritus, burrows, household contacts | “Is the itching worse at night? Does anyone else in your household have similar symptoms?” |
| Herpes zoster | Dermatomal distribution, preceded by pain or tingling | “Did you have pain, tingling, or burning in that area before the rash appeared? Did you have chickenpox as a child?” |
| Cellulitis | Unilateral, warm, tender, expanding erythema | “Did you notice any cuts, insect bites, or skin breaks before the redness started? Is the area warm and tender?” |
| Vasculitis | Palpable purpura, lower extremity predominance | “Have you had any joint pain, abdominal pain, blood in your urine, or recent infections like a sore throat?” |
| Systemic lupus erythematosus | Malar rash, photosensitivity, multisystem involvement | “Does sun exposure make your rash worse or cause new lesions? Have you had joint pain, mouth sores, or unusual fatigue?” |
| Secondary syphilis | Non-pruritic, palm and sole involvement, generalized | “Have you had any painless sores on your genitals in the past few months? Does the rash involve your palms or soles?” |
Medication and Social History
Medications Commonly Causing Rash
- Antibiotics — Penicillins, sulfonamides, cephalosporins (morbilliform eruptions most common)
- Anticonvulsants — Phenytoin, carbamazepine, lamotrigine (high risk for Stevens-Johnson syndrome and DRESS)
- Allopurinol — High risk for severe cutaneous adverse reactions, especially in HLA-B*58:01 carriers
- Nonsteroidal anti-inflammatory drugs — Fixed drug eruption, urticaria, photosensitivity
- Angiotensin-converting enzyme inhibitors — Angioedema (can occur years after starting)
- Chemotherapy agents — Hand-foot syndrome, radiation recall dermatitis
- Checkpoint inhibitors — Immune-mediated dermatitis, vitiligo, bullous reactions
- Targeted therapies — Epidermal growth factor receptor inhibitors cause acneiform eruptions
Social and Occupational History
- Sexual history: Risk factors for syphilis, herpes simplex virus, human immunodeficiency virus (disseminated infections)
- Travel history: Endemic mycoses, tropical infections, dengue, chikungunya
- Occupation: Healthcare (scabies, latex allergy), construction (contact dermatitis), outdoor work (Lyme disease, photodermatoses)
- Hobbies: Gardening (plant dermatitis), swimming (pool granuloma, hot tub folliculitis)
- Pets and animals: Tinea, scabies variants, cat scratch disease
- Living conditions: Crowding (scabies, bed bugs), homelessness (ectoparasites, infections)
- Immunosuppression: Human immunodeficiency virus status, transplant, chemotherapy, biologics
Critical Timeline Questions
| Time from Trigger to Rash | Likely Mechanism | Consider These Diagnoses |
|---|---|---|
| Minutes to hours | Type I hypersensitivity (IgE-mediated) | Urticaria, angioedema, anaphylaxis |
| 24-72 hours | Type IV hypersensitivity (T-cell mediated) | Contact dermatitis, fixed drug eruption |
| 7-14 days | Delayed T-cell sensitization | Morbilliform drug eruption, viral exanthem |
| 2-8 weeks | Complex immune dysregulation with viral reactivation | DRESS syndrome, serum sickness-like reaction |
| Months to years after exposure | Chronic sensitization or autoimmunity | Chronic contact dermatitis, drug-induced lupus |
History-Taking Pearl
Always ask about the first lesion. Where did it appear? What did it look like? The primary lesion and initial distribution often provide the most valuable diagnostic information. By the time patients present, secondary changes (excoriation, lichenification, impetiginization) may obscure the original morphology.
4. Physical Examination
A systematic head-to-toe approach for evaluating rash
Systematic Framework: Use the “Complete Skin Survey” approach. Examine the entire skin surface in good lighting, including often-missed areas: scalp, behind ears, axillae, umbilicus, interdigital spaces, nails, and mucous membranes. A focused examination limited to the chief complaint area frequently misses diagnostic clues.
General Inspection
- Overall appearance: Well or ill-appearing? Signs of systemic toxicity (lethargy, altered mental status)?
- Skin color: Pallor (anemia), jaundice (liver disease), generalized erythema (erythroderma, toxic shock syndrome)
- Respiratory status: Signs of airway compromise (stridor, wheezing) in patients with angioedema or anaphylaxis
- Hydration: Extensive skin loss leads to fluid and electrolyte derangements
- Body habitus: Obesity predisposes to intertrigo; malnutrition causes specific dermatoses
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Temperature | Fever (greater than 38°C) | Suggests infection, drug hypersensitivity syndrome, vasculitis, or systemic inflammatory condition; high fever with rash requires urgent evaluation |
| Heart Rate | Tachycardia | May indicate sepsis, anaphylaxis, pain, or systemic inflammation; compensatory response in erythroderma with fluid shifts |
| Blood Pressure | Hypotension | Concerning for sepsis, anaphylaxis, or toxic shock syndrome; requires immediate intervention |
| Respiratory Rate | Tachypnea | May indicate systemic illness, anaphylaxis, or anxiety; assess for airway involvement in angioedema |
| Oxygen Saturation | Hypoxia | Anaphylaxis with bronchospasm, underlying pulmonary disease, severe systemic illness |
Systematic Skin Examination
Step 1: Describe the Primary Lesion
| Feature | What to Assess | Documentation Example |
|---|---|---|
| Morphology | Macule, papule, plaque, vesicle, bulla, pustule, nodule, wheal, purpura | “Erythematous papules coalescing into plaques” |
| Size | Measure in millimeters or centimeters | “3-5 mm papules” or “10 cm plaque” |
| Color | Erythematous, violaceous, hyperpigmented, hypopigmented, yellow, brown | “Salmon-pink plaques with silvery scale” |
| Surface | Smooth, scaly, crusted, verrucous, umbilicated | “Smooth-topped papules” or “thick adherent scale” |
| Border | Well-defined, ill-defined, raised, flat | “Sharply demarcated plaques” or “poorly defined erythema” |
Step 2: Assess Distribution and Arrangement
Distribution Patterns
Generalized: Involves most of body surface (drug eruption, viral exanthem)
Localized: Confined to one region (contact dermatitis, herpes zoster)
Symmetric: Bilateral mirror image (systemic cause)
Photodistributed: Sun-exposed areas sparing shaded areas (lupus, drug photosensitivity)
Dermatomal: Follows nerve distribution (herpes zoster)
Acral: Hands and feet (secondary syphilis, hand-foot-mouth disease)
Arrangement Patterns
Grouped/Clustered: Herpes simplex, herpes zoster
Linear: Contact dermatitis (plant), Koebner phenomenon, dermatitis artefacta
Annular: Ring-shaped (tinea corporis, granuloma annulare, erythema migrans)
Reticular: Net-like (livedo reticularis)
Targetoid: Central dusky zone with surrounding rings (erythema multiforme)
Serpiginous: Snake-like, wavy (cutaneous larva migrans)
Step 3: Perform Key Maneuvers
| Maneuver | Technique | Positive Finding Indicates |
|---|---|---|
| Diascopy | Press glass slide firmly against lesion and observe | Blanching = vascular dilation (erythema); Non-blanching = extravasated blood (purpura) or infiltration |
| Nikolsky sign | Apply lateral pressure to normal-appearing skin near lesion | Positive (skin shears off) = pemphigus vulgaris, toxic epidermal necrolysis, staphylococcal scalded skin syndrome |
| Asboe-Hansen sign | Apply pressure to intact blister | Blister extends laterally = intraepidermal blister (pemphigus) |
| Darier sign | Stroke a lesion firmly | Urtication (wheal and flare) = mastocytosis |
| Dermographism | Stroke normal skin with blunt object | Wheal formation along stroke line = urticaria, mastocytosis |
| Auspitz sign | Remove scale from plaque | Pinpoint bleeding = psoriasis |
| Wood lamp examination | Examine skin under ultraviolet A light in dark room | Coral-red = erythrasma; Blue-green = Pseudomonas; Bright white = vitiligo; Yellow-green = tinea capitis (some species) |
Regional Examination: Don’t Miss These Areas
Head and Neck
Scalp: Psoriasis, seborrheic dermatitis, tinea capitis, folliculitis
Face: Malar rash (lupus), seborrheic dermatitis, rosacea, perioral dermatitis
Ears: Psoriasis (retroauricular), seborrheic dermatitis, contact dermatitis (jewelry)
Oral mucosa: Lichen planus, pemphigus, Stevens-Johnson syndrome, erythema multiforme
Trunk and Extremities
Axillae: Intertrigo, contact dermatitis, inverse psoriasis, acanthosis nigricans
Umbilicus: Psoriasis, contact dermatitis (nickel from belt buckles)
Extensor surfaces: Psoriasis, dermatitis herpetiformis
Flexural surfaces: Atopic dermatitis, inverse psoriasis
Hands, Feet, and Nails
Palms/Soles: Secondary syphilis, psoriasis, eczema, keratoderma, erythema multiforme
Web spaces: Scabies (pathognomonic), tinea pedis, candidiasis
Nails: Pitting (psoriasis), Beau lines, onycholysis, splinter hemorrhages
Periungual: Ragged cuticles (dermatomyositis), paronychia
Mucosal Examination
Always Examine Mucous Membranes
Mucosal involvement transforms many diagnoses from mild to severe. Stevens-Johnson syndrome requires mucosal involvement by definition. Always examine:
- Oral cavity: Erosions, ulcers, white plaques, hemorrhagic crusting of lips
- Conjunctivae: Injection, discharge, pseudomembrane formation (requires urgent ophthalmology consultation)
- Nasal mucosa: Crusting, erosions
- Genital mucosa: Erosions, ulcers (may require specific inquiry and examination)
Expected Findings by Etiology
| Condition | Primary Lesion | Distribution | Key Examination Findings |
|---|---|---|---|
| Morbilliform drug eruption | Erythematous macules and papules | Trunk → extremities, symmetric | Spares palms/soles initially; no mucosal involvement; patient appears well |
| Urticaria | Wheals (edematous pink plaques) | Variable, migratory | Individual lesions last less than 24 hours; dermographism; no residual marking |
| Contact dermatitis | Vesicles on erythematous base → eczematous plaques | Geometric, corresponds to contactant | Sharp borders; spares areas without contact; linear streaks suggest plant exposure |
| Psoriasis | Well-demarcated erythematous plaques with silvery scale | Extensor surfaces, scalp, sacrum | Auspitz sign; nail pitting and onycholysis; Koebner phenomenon |
| Herpes zoster | Grouped vesicles on erythematous base | Dermatomal, unilateral | Does not cross midline; pain often precedes rash; Hutchinson sign (nose tip) indicates eye involvement |
| Cellulitis | Ill-defined erythematous patch/plaque | Unilateral, often lower extremity | Warmth, tenderness, expanding border; may have portal of entry; lymphangitic streaking |
| Erythema multiforme | Targetoid lesions with three zones | Acral predominance (palms, soles, dorsal hands) | True targets with dusky center, pale ring, erythematous halo; mucosal involvement variable |
| Stevens-Johnson syndrome | Atypical targets, macules, bullae | Trunk predominant initially | Mucosal erosions (at least 2 sites); positive Nikolsky sign; skin pain; less than 10% body surface area detachment |
| Leukocytoclastic vasculitis | Palpable purpura | Lower extremities, dependent areas | Non-blanching on diascopy; may have vesicles, ulcers, or necrosis; check for systemic involvement |
| Scabies | Papules, vesicles, burrows | Web spaces, wrists, axillae, periumbilical, genitalia | Burrows (pathognomonic); excoriations from scratching; spares head in adults |
Important Teaching Point
Context determines significance. The physical examination findings must be interpreted in clinical context. A non-tender, well-appearing patient with scattered purpura likely has a benign cause (senile purpura, trauma), while purpura with fever and ill appearance suggests life-threatening infection or vasculitis. Similarly, a few vesicles on the lip are herpes labialis, but widespread vesicles with mucosal involvement and skin pain may be Stevens-Johnson syndrome. Always integrate examination findings with history and vital signs.
Examination Pearls
- Photograph the rash: Rashes evolve; documentation aids diagnosis and follow-up
- Palpate every rash: You cannot distinguish papules from macules, or detect purpura, without touch
- Examine in good lighting: Subtle color changes and scale are missed in dim environments
- Look for “unroofed” lesions: The edge of a ruptured blister or pustule reveals the depth of the lesion
- Ask about timing of individual lesions: Wheals resolve in less than 24 hours; fixed lesions suggest different pathology
5. Differential Diagnosis
Systematic approach organized by probability, morphology, and clinical features
Acute Rash (Duration: Less than 2 weeks)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 70%) | Viral exanthem | Morbilliform; prodrome of fever, malaise; often in outbreak setting | Petechiae, mucosal involvement, severe systemic symptoms |
| Drug eruption (morbilliform) | Symmetric, trunk to extremities; 7-14 days after new medication | Facial edema, mucosal lesions, blistering, eosinophilia, organ dysfunction | |
| Urticaria (acute) | Migratory wheals; individual lesions last less than 24 hours; intense pruritus | Angioedema (lips, tongue, throat), respiratory symptoms, hypotension | |
| Contact dermatitis (acute) | Geometric distribution; vesicles on erythematous base; pruritic | Widespread involvement, systemic symptoms (suggests systemic contact) | |
| Cellulitis | Unilateral, expanding erythema; warmth, tenderness; portal of entry | Rapid progression, crepitus, pain out of proportion, bullae, necrosis | |
| LESS COMMON (approximately 20%) | Herpes zoster | Dermatomal; grouped vesicles; preceded by pain | Dissemination, Hutchinson sign (eye involvement), immunocompromised host |
| Erythema multiforme | Targetoid lesions; acral distribution; often post-herpes simplex virus | Mucosal involvement (may indicate Stevens-Johnson syndrome) | |
| Scabies | Burrows, web spaces; intense nocturnal pruritus; household contacts | Crusted (Norwegian) scabies in immunocompromised | |
| Insect bite reaction | Grouped papules; exposed areas; central punctum | Widespread urticaria, systemic symptoms (anaphylaxis) | |
| UNCOMMON BUT SERIOUS (approximately 10%) | Stevens-Johnson syndrome / Toxic epidermal necrolysis | Atypical targets, bullae; mucosal erosions; skin pain; recent drug exposure | Greater than 10% body surface area (toxic epidermal necrolysis); high mortality |
| Meningococcemia | Petechiae and purpura; fever; rapid progression; ill-appearing | All cases are emergent; purpura fulminans indicates disseminated intravascular coagulation | |
| Necrotizing fasciitis | Pain out of proportion; rapid spread; systemic toxicity; crepitus | Surgical emergency; mortality increases with delay | |
| Rocky Mountain spotted fever | Petechial rash starting on wrists/ankles → centripetal; fever, headache | Delay in treatment increases mortality; treat empirically if suspected | |
| Toxic shock syndrome | Diffuse erythroderma; fever; hypotension; multiorgan dysfunction | Emergent; requires intensive care unit admission |
Chronic Rash (Duration: Greater than 6 weeks)
Step-by-Step Approach to Chronic Rash:
- Step 1: Identify the primary lesion morphology — Is it papulosquamous, eczematous, vesiculobullous, or purpuric?
- Step 2: Assess distribution — Does the pattern suggest a specific diagnosis (photodistributed, dermatomal, extensor)?
- Step 3: Consider the “Big Four” causes of chronic rash — Eczema, psoriasis, fungal infection, and drug reaction
- Step 4: Look for systemic clues — Joint pain, photosensitivity, oral ulcers, and other features suggesting connective tissue disease
- Step 5: Consider biopsy if diagnosis remains unclear after clinical assessment
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Atopic dermatitis (eczema) | 10-20% of population | Flexural distribution in adults; pruritus; personal or family history of atopy; lichenification |
| Psoriasis | 2-3% of population | Well-demarcated plaques with silvery scale; extensor surfaces; nail changes; Koebner phenomenon | |
| Seborrheic dermatitis | 3-5% of population | Greasy yellow scale; nasolabial folds, eyebrows, scalp; may flare with stress | |
| Chronic urticaria | 0.5-1% of population | Recurrent wheals for greater than 6 weeks; often idiopathic; individual lesions transient | |
| LESS COMMON | Tinea corporis / Tinea cruris | Variable | Annular plaques with central clearing and active scaly border; potassium hydroxide positive |
| Lichen planus | 0.5-1% of population | Purple, polygonal, planar papules; Wickham striae; oral involvement common | |
| Pityriasis rosea | Variable (often subacute) | Herald patch followed by “Christmas tree” distribution; oval lesions along skin lines | |
| Nummular eczema | Variable | Coin-shaped eczematous plaques; often on extremities; very pruritic | |
| UNCOMMON BUT IMPORTANT | Cutaneous lupus erythematosus | Rare | Photodistributed; malar rash sparing nasolabial folds; discoid lesions with scarring |
| Dermatomyositis | Rare | Heliotrope rash (periorbital); Gottron papules (knuckles); proximal muscle weakness | |
| Cutaneous T-cell lymphoma (mycosis fungoides) | Rare | Patches and plaques in sun-protected areas (“bathing suit distribution”); may evolve over years | |
| Bullous pemphigoid | Rare (elderly) | Tense bullae on erythematous or normal skin; pruritus may precede blisters; elderly patients | |
| Pemphigus vulgaris | Rare | Flaccid bullae that rupture easily; oral erosions often first; positive Nikolsky sign |
Morphology-Based Differential
Papulosquamous
Psoriasis
Lichen planus
Pityriasis rosea
Secondary syphilis
Tinea corporis
Seborrheic dermatitis
Eczematous
Atopic dermatitis
Contact dermatitis
Nummular eczema
Stasis dermatitis
Asteatotic eczema
Dyshidrotic eczema
Vesiculobullous
Herpes simplex / zoster
Bullous pemphigoid
Pemphigus vulgaris
Dermatitis herpetiformis
Stevens-Johnson syndrome
Contact dermatitis (acute)
Purpuric / Vascular
Leukocytoclastic vasculitis
Henoch-Schönlein purpura (IgA vasculitis)
Thrombocytopenia
Meningococcemia
Rocky Mountain spotted fever
Senile purpura
Drug-Induced Rash
| Reaction Type | Common Culprits | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Morbilliform (exanthematous) | Penicillins, sulfonamides, cephalosporins, anticonvulsants, allopurinol | Symmetric macules and papules; starts on trunk; mild pruritus; spares face initially | 1-2 weeks |
| Urticarial | Penicillins, nonsteroidal anti-inflammatory drugs, opioids, radiocontrast | Wheals, angioedema; may be IgE-mediated or direct mast cell activation | Hours to days |
| Fixed drug eruption | Trimethoprim-sulfamethoxazole, nonsteroidal anti-inflammatory drugs, tetracyclines, phenolphthalein | Round, dusky plaques; recur in same location with re-exposure; may blister | Days to weeks (hyperpigmentation may persist) |
| Photosensitivity | Tetracyclines (especially doxycycline), fluoroquinolones, thiazides, amiodarone | Exaggerated sunburn in sun-exposed areas; sharp cutoff at clothing lines | Days to weeks after stopping and sun avoidance |
| Stevens-Johnson syndrome / Toxic epidermal necrolysis | Sulfonamides, anticonvulsants (carbamazepine, phenytoin, lamotrigine), allopurinol, nonsteroidal anti-inflammatory drugs | Mucosal erosions; skin pain; atypical targets; epidermal detachment | Weeks to months; may have long-term sequelae |
| Drug reaction with eosinophilia and systemic symptoms (DRESS) | Anticonvulsants, allopurinol, sulfonamides, dapsone, minocycline | Facial edema; morbilliform rash; fever; lymphadenopathy; eosinophilia; hepatitis | Weeks to months; may relapse |
| Acute generalized exanthematous pustulosis | Antibiotics (especially beta-lactams), calcium channel blockers, hydroxychloroquine | Rapid onset of hundreds of sterile pustules on erythematous base; fever; neutrophilia | Less than 2 weeks (rapid resolution) |
| Drug-induced lupus | Hydralazine, procainamide, isoniazid, tumor necrosis factor inhibitors | Photosensitive rash; arthralgia; serositis; positive antihistone antibodies | Weeks to months after drug cessation |
| Lichenoid drug eruption | Thiazides, beta-blockers, antimalarials, gold, angiotensin-converting enzyme inhibitors | Resembles lichen planus; may have photodistribution; longer latency | Months (may persist long after stopping) |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Dermatomal vesicles | Herpes zoster | Start antiviral within 72 hours; assess for eye involvement |
| Targetoid lesions on palms | Erythema multiforme | Look for mucosal involvement; identify trigger (herpes simplex virus, drugs) |
| Silvery scale on elbows/knees | Psoriasis | Check nails, scalp, intergluteal cleft; screen for psoriatic arthritis |
| Burrows in web spaces | Scabies | Treat patient and all close contacts simultaneously; wash bedding |
| Annular plaque with central clearing | Tinea corporis (or granuloma annulare) | Potassium hydroxide preparation; if negative consider granuloma annulare |
| Malar rash sparing nasolabial folds | Systemic lupus erythematosus | Antinuclear antibody, complete blood count, urinalysis, comprehensive metabolic panel |
| Palpable purpura on lower extremities | Leukocytoclastic vasculitis | Urinalysis (glomerulonephritis); biopsy if diagnosis unclear |
| Rash on palms and soles (non-pruritic) | Secondary syphilis | Rapid plasma reagin or venereal disease research laboratory test; human immunodeficiency virus testing |
| Herald patch followed by “Christmas tree” pattern | Pityriasis rosea | Reassurance (self-limiting); consider rapid plasma reagin to exclude syphilis |
| Heliotrope rash with proximal weakness | Dermatomyositis | Creatine kinase, aldolase; electromyography; malignancy screening |
| Petechiae with fever and headache | Meningococcemia or Rocky Mountain spotted fever | Emergent blood cultures, lumbar puncture; empiric antibiotics immediately |
| Tense bullae in elderly patient | Bullous pemphigoid | Skin biopsy for histology and direct immunofluorescence |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
Key Principle: Many rashes can be diagnosed clinically without laboratory testing. Investigations should be targeted based on the differential diagnosis, not ordered as a “rash panel.” The clinical examination remains the most important diagnostic tool in dermatology.
Baseline Investigations for Selected Patients
Not all patients with rash require laboratory testing. Consider baseline investigations when:
- Systemic symptoms are present (fever, malaise, weight loss)
- Rash is widespread or severe
- Drug hypersensitivity syndrome is suspected
- Autoimmune or inflammatory condition is considered
- Diagnosis is uncertain after clinical assessment
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count with differential | Screen for infection, eosinophilia, cytopenias | Eosinophilia (drug reaction, parasites); atypical lymphocytes (viral); leukocytosis (infection); thrombocytopenia (vasculitis, disseminated intravascular coagulation) | Eosinophilia greater than 1.5 × 10⁹/L with rash suggests drug reaction; peripheral smear if atypical cells |
| Comprehensive metabolic panel | Assess organ function, especially liver and kidney | Elevated transaminases (DRESS, hepatitis); renal dysfunction (vasculitis, drug toxicity) | Essential in suspected drug hypersensitivity; transaminases greater than 3 times upper limit of normal is significant |
| Urinalysis | Screen for renal involvement | Hematuria, proteinuria (vasculitis, lupus nephritis, IgA vasculitis) | Critical in vasculitis workup; repeat if initially normal but clinical suspicion high |
| Inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) | Assess degree of systemic inflammation | Elevation suggests infection, vasculitis, autoimmune disease | Non-specific; useful for monitoring but rarely diagnostic alone |
| Blood cultures | Identify bacteremia in suspected infectious etiology | Positive cultures guide antibiotic therapy | Obtain before antibiotics if sepsis, endocarditis, or meningococcemia suspected |
Targeted Investigations by Suspected Etiology
If Suspecting Drug Hypersensitivity Syndrome (DRESS)
First-Line Tests
- Complete blood count with differential: Eosinophilia (greater than 0.7 × 10⁹/L) or atypical lymphocytes
- Liver function tests: Alanine aminotransferase greater than 2 times upper limit of normal
- Renal function: Creatinine elevation indicates renal involvement
Second-Line Tests
- Human herpesvirus 6 polymerase chain reaction: Reactivation supports DRESS diagnosis
- Echocardiogram: If myocarditis suspected (chest pain, troponin elevation)
- Thyroid function: Check at presentation and 2-3 months later (autoimmune thyroiditis can develop)
If Suspecting Autoimmune or Connective Tissue Disease
First-Line Tests
- Antinuclear antibody: Screening test; positive in lupus, dermatomyositis, scleroderma
- Complete blood count: Cytopenias (autoimmune)
- Urinalysis: Renal involvement in lupus
- Complement levels (C3, C4): Low in active lupus
Second-Line Tests (if antinuclear antibody positive)
- Anti-double-stranded DNA: Specific for systemic lupus erythematosus
- Anti-Smith, anti-ribonucleoprotein: Lupus and mixed connective tissue disease
- Anti-Ro (SSA), anti-La (SSB): Subacute cutaneous lupus, Sjögren syndrome
- Creatine kinase, aldolase: If dermatomyositis suspected
- Myositis-specific antibodies: Anti-Jo-1, anti-Mi-2 for dermatomyositis
If Suspecting Vasculitis
First-Line Tests
- Urinalysis: Hematuria, red blood cell casts (glomerulonephritis)
- Renal function: Creatinine elevation
- Inflammatory markers: Erythrocyte sedimentation rate, C-reactive protein elevated
- Skin biopsy: Leukocytoclastic vasculitis; direct immunofluorescence for IgA (IgA vasculitis)
Second-Line Tests
- Antineutrophil cytoplasmic antibody: If systemic vasculitis suspected (granulomatosis with polyangiitis, microscopic polyangiitis)
- Cryoglobulins: If cryoglobulinemic vasculitis suspected (hepatitis C associated)
- Hepatitis B and C serology: Associated with vasculitis
- Complement levels: Low in hypocomplementemic urticarial vasculitis
If Suspecting Infection
Bacterial Infections
- Blood cultures: Before antibiotics in sepsis, endocarditis
- Wound culture: If purulent drainage or abscess present
- Antistreptolysin O titer: Post-streptococcal vasculitis, guttate psoriasis trigger
- Rapid plasma reagin or venereal disease research laboratory: Syphilis screening
Viral and Other Infections
- Human immunodeficiency virus antibody/antigen: New diagnosis may present with rash; affects differential
- Hepatitis panel: Hepatitis B and C associated with vasculitis, urticaria
- Herpes simplex virus polymerase chain reaction or direct fluorescent antibody: Vesicular lesions
- Varicella-zoster virus polymerase chain reaction: Atypical presentations or immunocompromised
Skin Biopsy: When and How
Indications for Skin Biopsy
- Diagnosis uncertain after clinical assessment
- Suspected malignancy (cutaneous T-cell lymphoma, melanoma)
- Suspected autoimmune blistering disease (requires direct immunofluorescence)
- Vasculitis confirmation
- Chronic rash unresponsive to empiric treatment
- Atypical presentation requiring histological characterization
| Biopsy Type | Technique | Best For | Special Considerations |
|---|---|---|---|
| Punch biopsy (4 mm) | Circular blade removes full-thickness specimen | Most inflammatory conditions; vasculitis; panniculitis | Standard technique; include dermis and subcutis for panniculitis |
| Shave biopsy | Superficial horizontal excision | Epidermal lesions; suspected basal cell or squamous cell carcinoma | Inadequate for melanoma; does not assess depth |
| Incisional biopsy | Elliptical excision of portion of lesion | Large lesions; panniculitis; deep processes | Include subcutaneous fat for panniculitis |
| Direct immunofluorescence | Separate specimen in Michel medium (not formalin) | Autoimmune blistering diseases; lupus; vasculitis | Biopsy perilesional skin for bullous diseases; lesional skin for lupus |
Bedside Diagnostic Tests
| Test | Technique | Interpretation | Conditions Diagnosed |
|---|---|---|---|
| Potassium hydroxide (KOH) preparation | Scrape scale onto slide; add 10-20% KOH; heat gently; examine under microscope | Hyphae and/or spores visible | Dermatophyte infections (tinea), candidiasis |
| Tzanck smear | Scrape base of vesicle; stain with Giemsa or Wright stain | Multinucleated giant cells | Herpes simplex virus, varicella-zoster virus (does not distinguish between them) |
| Scabies preparation | Apply mineral oil; scrape burrow; examine under microscope | Mites, eggs, or fecal pellets (scybala) | Scabies |
| Wood lamp examination | Examine skin under ultraviolet A (365 nm) in dark room | Coral-red (erythrasma), blue-green (Pseudomonas), bright white (vitiligo) | Erythrasma, tinea capitis (some species), vitiligo, Pseudomonas infection |
| Dermoscopy | Examine lesion with polarized or non-polarized dermatoscope | Pattern recognition for pigmented and non-pigmented lesions | Melanoma, basal cell carcinoma, scabies (burrows), psoriasis (red dots) |
Empiric Treatment Trials as Diagnostic Tools
Sequential Empiric Therapy Approach
When diagnosis is uncertain but clinical suspicion is high, empiric treatment trials can serve as diagnostic tools. Response to therapy supports the diagnosis. This approach is particularly useful for conditions where definitive testing is invasive, unavailable, or has limited sensitivity.
- Suspected contact dermatitis: Remove suspected contactant and apply topical corticosteroid for 2 weeks — clearance supports diagnosis
- Suspected tinea: Topical antifungal for 2-4 weeks — response suggests fungal etiology (if KOH negative or unavailable)
- Suspected scabies: Permethrin treatment for patient and contacts — resolution of pruritus in 2-4 weeks supports diagnosis
- Suspected drug eruption: Discontinue suspected medication — improvement within 1-2 weeks supports drug etiology
When to Refer to Dermatology
| Situation | Urgency | Reason |
|---|---|---|
| Stevens-Johnson syndrome / Toxic epidermal necrolysis | EMERGENT | Requires specialized care; potential burn unit transfer; high mortality |
| Suspected pemphigus or pemphigoid with active blistering | URGENT | Biopsy with direct immunofluorescence required; needs systemic immunosuppression |
| Suspected cutaneous malignancy | URGENT | Biopsy and staging required; delays worsen outcomes |
| Chronic rash unresponsive to treatment | ROUTINE | May benefit from biopsy, patch testing, or specialized therapy |
| Diagnostic uncertainty | ROUTINE | Dermatology expertise in pattern recognition and biopsy interpretation |
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Petechiae/purpura with fever, hypotension, or altered mental status | EMERGENT | Obtain blood cultures; start broad-spectrum antibiotics immediately; do not wait for results; consider meningococcemia, Rocky Mountain spotted fever |
| Widespread blistering with mucosal involvement and skin pain | EMERGENT | Stop all non-essential medications; calculate body surface area involvement; consult dermatology and burn unit; supportive care; consider Stevens-Johnson syndrome/toxic epidermal necrolysis |
| Rapidly spreading erythema with pain out of proportion, crepitus, or necrosis | EMERGENT | Surgical consultation immediately; broad-spectrum antibiotics; imaging if diagnosis uncertain; do not delay for imaging if clinical suspicion high; consider necrotizing fasciitis |
| Urticaria with angioedema, stridor, or hypotension | EMERGENT | Intramuscular epinephrine; secure airway; intravenous fluids; antihistamines and corticosteroids; observe for biphasic reaction |
| Diffuse erythroderma with fever and hypotension | EMERGENT | Fluid resuscitation; assess for toxic shock syndrome; blood cultures; remove tampons or wound packing; broad-spectrum antibiotics |
| Drug rash with fever, facial edema, lymphadenopathy, or eosinophilia | URGENT | Stop culprit drug immediately; check complete blood count, liver function tests, renal function; consider drug reaction with eosinophilia and systemic symptoms (DRESS); may need admission |
| Dermatomal vesicles involving the face (V1 distribution) | URGENT | Start antiviral within 72 hours; urgent ophthalmology referral (Hutchinson sign or any eye symptoms); assess for herpes zoster ophthalmicus |
| Expanding cellulitis not responding to oral antibiotics | URGENT | Admit for intravenous antibiotics; mark borders; consider resistant organisms, abscess, or alternative diagnosis |
| Chronic rash without red flags | ROUTINE | Outpatient evaluation; systematic workup; dermatology referral if diagnosis uncertain or treatment refractory |
| Localized, non-progressive rash in well-appearing patient | ROUTINE | Clinical diagnosis; empiric treatment if appropriate; follow-up to assess response |
Step 2: Classify by Acuity and Morphology
Acute Rash (less than 2 weeks)
Proceed to Algorithm A
Focus on: infections, drug reactions, urticaria, contact dermatitis
Subacute Rash (2-6 weeks)
Proceed to Algorithm B
Focus on: pityriasis rosea, secondary syphilis, resolving acute process, early chronic condition
Chronic Rash (greater than 6 weeks)
Proceed to Algorithm C
Focus on: eczema, psoriasis, autoimmune conditions, cutaneous malignancy
Step 3: Follow the Appropriate Algorithm
Algorithm A: Acute Rash
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Symmetric morbilliform rash + new medication in past 2 weeks + no mucosal involvement | Morbilliform drug eruption | Stop suspected drug; supportive care with antihistamines and topical corticosteroids; monitor for progression |
| Migratory wheals + individual lesions resolve in less than 24 hours + no residual marks | Acute urticaria | Identify and avoid trigger; second-generation antihistamine; short course of corticosteroids if severe |
| Geometric/linear vesicles on erythematous base + exposed area + history of exposure | Allergic contact dermatitis | Remove contactant; topical corticosteroid (high potency); oral corticosteroids if widespread |
| Grouped vesicles + dermatomal distribution + preceded by pain | Herpes zoster | Antiviral within 72 hours; pain management; ophthalmology if facial involvement |
| Unilateral warm, tender, expanding erythema + portal of entry | Cellulitis | Antibiotics covering Streptococcus and Staphylococcus; mark borders; elevate affected limb |
| Morbilliform rash + prodrome of fever/malaise + sick contacts or outbreak | Viral exanthem | Supportive care; isolate if measles suspected; consider testing if epidemiologically relevant |
| Targetoid lesions on palms/soles + recent herpes simplex virus infection | Erythema multiforme | Examine mucous membranes; supportive care; treat herpes simplex virus if active; prophylaxis if recurrent |
Algorithm B: Subacute Rash (2-6 weeks)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Herald patch followed by oval papulosquamous lesions along skin lines (“Christmas tree” pattern) | Pityriasis rosea | Reassurance (self-limiting in 6-8 weeks); symptomatic treatment for pruritus; consider rapid plasma reagin to exclude syphilis |
| Non-pruritic papulosquamous rash + palm/sole involvement + lymphadenopathy | Secondary syphilis | Rapid plasma reagin and confirmatory testing; treat with penicillin; human immunodeficiency virus testing; contact tracing |
| Acute rash persisting beyond expected course + still improving | Resolving acute process | Continue current management; monitor for complete resolution; investigate further if not improving |
| New rash with systemic symptoms + drug started 2-8 weeks ago | Drug reaction with eosinophilia and systemic symptoms (DRESS) | Stop drug immediately; check complete blood count with differential, liver function tests, renal function; admit if organ involvement |
Algorithm C: Chronic Rash (greater than 6 weeks)
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Pruritic eczematous patches in flexural areas + personal/family history of atopy | Atopic dermatitis | Emollients; topical corticosteroids; trigger avoidance; consider calcineurin inhibitors for face/folds |
| Well-demarcated erythematous plaques with silvery scale + extensor surfaces + nail changes | Psoriasis | Topical therapy (corticosteroids, vitamin D analogues); phototherapy or systemic therapy if extensive; screen for psoriatic arthritis |
| Annular scaly plaques with central clearing + positive potassium hydroxide preparation | Tinea corporis | Topical antifungal for limited disease; oral antifungal if extensive, follicular involvement, or treatment failure |
| Recurrent wheals for greater than 6 weeks + individual lesions transient + no identifiable trigger | Chronic spontaneous urticaria | Second-generation antihistamine (up to 4 times standard dose); omalizumab if refractory; limited workup unless atypical features |
| Photodistributed rash + malar erythema sparing nasolabial folds + systemic symptoms | Cutaneous lupus erythematosus | Antinuclear antibody and serologic workup; sun protection; topical corticosteroids; hydroxychloroquine; rheumatology referral |
| Persistent patches/plaques in sun-protected areas + older patient + no response to topical treatment | Cutaneous T-cell lymphoma (mycosis fungoides) | Skin biopsy (may need multiple); dermatology and oncology referral; staging workup |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient develops rash while hospitalized on multiple new medications | Review medication timeline; stop most likely culprit (usually most recently started); examine for mucosal involvement and systemic signs | Monitor closely; if DRESS suspected, check complete blood count, liver function tests, renal function daily; dermatology consultation |
| Rash with unclear morphology due to excoriations | Look for primary lesions at periphery of affected area; ask patient to describe initial appearance; examine areas patient cannot scratch | If unable to identify primary lesion, treat symptomatically and reassess when excoriations heal; consider biopsy of intact lesion |
| Widespread rash in immunocompromised patient | Broaden differential to include opportunistic infections (disseminated herpes, fungal); lower threshold for biopsy and cultures | Consider varicella-zoster virus and herpes simplex virus polymerase chain reaction; fungal cultures; tissue biopsy; infectious disease consultation |
| Elderly patient with new tense bullae | Consider bullous pemphigoid; examine oral mucosa; assess Nikolsky sign | Skin biopsy for histology and direct immunofluorescence (perilesional skin); start moderate-potency topical corticosteroid while awaiting results |
| Rash that looks like psoriasis but patient has human immunodeficiency virus | Consider seborrheic dermatitis, psoriasis (may be more severe in human immunodeficiency virus), or secondary syphilis | Rapid plasma reagin test; standard psoriasis treatment (but avoid systemic immunosuppression if CD4 low); optimize human immunodeficiency virus treatment |
| Contact dermatitis but cannot identify contactant | Detailed history of all products used on skin, occupation, hobbies; consider airborne or systemic contact | Referral for patch testing; systematic elimination of suspected products |
| Chronic rash unresponsive to empiric treatment | Reassess diagnosis; consider biopsy if not already performed; evaluate for treatment adherence | Dermatology referral; consider alternative diagnoses (cutaneous T-cell lymphoma, drug eruption from chronic medication) |
Troubleshooting Refractory Rash
Ask These Questions When Rash Does Not Respond
- Is the diagnosis correct? — Consider biopsy if not already done; reassess morphology and distribution
- Is there ongoing exposure? — Contact allergen still present; medication not discontinued; infection source not eliminated
- Is treatment adequate? — Corticosteroid potency appropriate; duration sufficient; coverage for actual organism
- Is the patient adherent? — Applying enough medication; completing full course; using as directed
- Are there multiple overlapping conditions? — Contact dermatitis superimposed on atopic dermatitis; secondary infection complicating primary rash
- Is there secondary infection? — Impetiginization of eczema; bacterial superinfection requiring antibiotics
- Are there underlying factors? — Undiagnosed human immunodeficiency virus; diabetes; malignancy; medication causing or exacerbating rash
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
The primary lesion is paramount: Identifying the primary lesion morphology (macule, papule, vesicle, pustule, wheal) is the single most important step in dermatological diagnosis. Secondary changes from scratching or treatment obscure the diagnosis.
Distribution tells the story: Symmetric distribution suggests systemic cause (drug, viral, autoimmune). Asymmetric or localized distribution suggests external cause (contact, infection). Dermatomal distribution is virtually pathognomonic for herpes zoster.
Diascopy distinguishes erythema from purpura: Press a glass slide against the lesion. Blanching indicates vasodilation (erythema). Non-blanching indicates extravasated blood (purpura) and demands a different differential including vasculitis, coagulopathy, and sepsis.
Mucosal involvement changes everything: A morbilliform drug rash is usually benign, but mucosal erosions transform it into potential Stevens-Johnson syndrome. Always examine the oral cavity, conjunctivae, and ask about genital symptoms.
Drug timing guides suspicion: Type I reactions occur within minutes to hours. Morbilliform eruptions occur 7-14 days after starting a new drug. Drug reaction with eosinophilia and systemic symptoms (DRESS) occurs 2-8 weeks after initiation. Fixed drug eruption recurs within hours of re-exposure.
Wheals that persist beyond 24 hours are not simple urticaria: True urticarial lesions resolve completely within 24 hours and leave no mark. If individual lesions persist longer or leave bruising, consider urticarial vasculitis and perform biopsy.
Always consider syphilis: Secondary syphilis is “the great imitator” and can present with almost any morphology. A non-pruritic rash involving the palms and soles should prompt serologic testing, especially in sexually active patients.
Photograph every rash: Rashes evolve rapidly. A photograph at presentation provides invaluable documentation for comparison, consultation, and follow-up assessment.
Critical Pitfalls to Avoid
Dismissing skin pain: Pain out of proportion to visible findings is a red flag for necrotizing fasciitis and early toxic epidermal necrolysis. A patient who says their skin “hurts” rather than “itches” requires careful evaluation.
Attributing all rashes to allergy: Not every rash is allergic. Viral exanthems, autoimmune conditions, infections, and malignancies can all present with rash. A thorough differential prevents delayed diagnosis of serious conditions.
Missing drug reaction with eosinophilia and systemic symptoms (DRESS): This severe reaction presents 2-8 weeks after drug initiation with facial edema, rash, fever, and eosinophilia. The delayed onset often leads to missed diagnosis. Always check liver function tests, renal function, and complete blood count in any patient with extensive drug eruption.
Treating cellulitis without considering mimics: Stasis dermatitis, deep vein thrombosis, contact dermatitis, and gout can all mimic cellulitis. Bilateral “cellulitis” is almost never bilateral infection—consider stasis dermatitis. Failure to respond to antibiotics should prompt reconsideration of the diagnosis.
Ignoring the immunocompromised host: In immunocompromised patients, common conditions present atypically, and unusual infections must be considered. Disseminated herpes, invasive fungal infections, and drug reactions may all look different. Have a lower threshold for biopsy and cultures.
Applying topical steroids to undiagnosed facial rash: High-potency topical corticosteroids on the face can cause steroid rosacea, atrophy, and telangiectasia. Never prescribe potent topical steroids for facial rash without a clear diagnosis and plan for limited duration.
Forgetting to examine the whole skin: A focused examination of only the chief complaint area misses important diagnostic clues. Nail changes, scalp involvement, oral lesions, and genital findings often clinch the diagnosis.
Delaying treatment for Rocky Mountain spotted fever: This infection has significant mortality if treatment is delayed. Empiric doxycycline should be started immediately based on clinical suspicion (fever, headache, rash, tick exposure) without waiting for serologic confirmation.
Key Takeaways
- Accurate description of the primary lesion morphology is the foundation of dermatological diagnosis—learn the vocabulary and use it precisely.
- Red flags requiring urgent evaluation include mucosal involvement, skin pain, petechiae or purpura with fever, widespread blistering, and rapidly spreading erythema with systemic toxicity.
- Use the “RASHES” mnemonic for systematic history: Recent exposures, Appearance and evolution, Symptoms associated, History personal and family, Exact location and spread, Systemic review.
- Distribution pattern provides critical diagnostic clues: symmetric suggests systemic, dermatomal suggests zoster, photodistributed suggests lupus or drug photosensitivity, acral suggests erythema multiforme or secondary syphilis.
- Drug eruptions have predictable timing: minutes to hours for urticaria/anaphylaxis, 7-14 days for morbilliform eruption, 2-8 weeks for drug reaction with eosinophilia and systemic symptoms (DRESS).
- Always perform diascopy on any red or purple lesion to distinguish blanching erythema from non-blanching purpura—this fundamentally changes the differential diagnosis.
- Many rashes are diagnosed clinically without laboratory testing. Target investigations based on clinical suspicion rather than ordering a “rash panel.”
- When diagnosis is uncertain, skin biopsy is valuable—but the site and technique matter. Biopsy an established lesion, include adequate depth, and send for direct immunofluorescence if autoimmune blistering disease is suspected.
- Consider secondary syphilis in any patient with a non-pruritic rash involving the palms and soles—serologic testing is simple and the diagnosis is easily missed.
- If a rash is not responding to treatment, reassess the diagnosis. Consider biopsy, alternative diagnoses, ongoing exposure, inadequate treatment, non-adherence, or secondary infection.
Quick Reference Algorithm
Systematic Approach to Rash:
- Assess urgency: Check for red flags (mucosal involvement, skin pain, petechiae with fever, widespread blistering, systemic toxicity). If present, initiate urgent workup and treatment.
- Identify the primary lesion: Is it a macule, papule, plaque, vesicle, bulla, pustule, wheal, nodule, or purpura? This narrows the differential immediately.
- Characterize the distribution: Localized versus generalized? Symmetric versus asymmetric? Photodistributed, dermatomal, flexural, extensor, or acral?
- Take a focused history: Use “RASHES” mnemonic. Pay special attention to recent medications (past 8 weeks), timeline of evolution, associated symptoms, and exposures.
- Perform key examination maneuvers: Diascopy for any red or purple lesion. Nikolsky sign if blistering. Dermoscopy if available. Examine nails, scalp, and mucous membranes.
- Generate a probability-based differential: Start with common causes, but always consider serious diagnoses that require urgent treatment.
- Target investigations: Order tests based on clinical suspicion, not as a routine panel. Consider biopsy if diagnosis remains unclear.
- Initiate treatment and arrange follow-up: Treat empirically if diagnosis is confident. Reassess if no improvement. Refer to dermatology for refractory or diagnostically challenging cases.